David A Beebe
Overview
Explore the profile of David A Beebe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith K, Wang W, Miller M, Boucher M, Reynold J, Daurio N, et al.
Cell Mol Gastroenterol Hepatol
. 2023 Oct;
17(2):279-291.
PMID: 37844795
Background & Aims: Nonalcoholic fatty liver disease (NAFLD), and its more severe form, nonalcoholic steatohepatitis (NASH), is the leading cause for liver failure and liver cancer. Although the etiology is...
2.
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Ross T, Crowley C, Kelly K, Rinaldi A, Beebe D, Lech M, et al.
Cell Mol Gastroenterol Hepatol
. 2020 Jun;
10(4):829-851.
PMID: 32526482
Background & Aims: Disordered metabolism, steatosis, hepatic inflammation, and fibrosis contribute to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) catalyzes the first committed step in de novo lipogenesis...
3.
Linden M, Ross T, Beebe D, Gorgoglione M, Hamilton K, Miller B, et al.
Metabolism
. 2019 May;
97:68-80.
PMID: 31132381
Purpose: Exercise is recommended in addition to pharmacotherapies for the management of type 2 diabetes, but metformin and exercise training may have non-additive or even inhibitory effects on exercise-induced improvements...
4.
Huard K, Ahn K, Amor P, Beebe D, Borzilleri K, Chrunyk B, et al.
J Med Chem
. 2017 Aug;
60(18):7835-7849.
PMID: 28853885
Increased fructose consumption and its subsequent metabolism have been implicated in hepatic steatosis, dyslipidemia, obesity, and insulin resistance in humans. Since ketohexokinase (KHK) is the principal enzyme responsible for fructose...
5.
Griffith D, Dow R, Huard K, Edmonds D, Bagley S, Polivkova J, et al.
J Med Chem
. 2013 Aug;
56(17):7110-9.
PMID: 23981033
Acetyl-CoA carboxylase (ACC) catalyzes the rate-determining step in de novo lipogenesis and plays a crucial role in the regulation of fatty acid oxidation. Alterations in lipid metabolism are believed to...
6.
Knight Jr D, Smith A, Schroeder R, Huang C, Beebe D, Sokolowski S, et al.
J Transl Med
. 2013 Apr;
11:101.
PMID: 23607770
Background: Endothelium-dependent flow mediated dilation (FMD) and pulse-wave velocity (PWV), are used as measures of vascular health and predictors of cardiovascular risk in clinical studies, and both are age-dependent. Numbers...
7.
Andrews K, Beebe D, Benbow J, Boyer D, Doran S, Hui Y, et al.
Bioorg Med Chem Lett
. 2011 Feb;
21(6):1810-4.
PMID: 21324688
A 3-amino-4-substituted pyrrolidine series of dipeptidyl peptidase IV (DPP-4) inhibitors was rapidly developed into a candidate series by identification of a polar valerolactam replacement for the lipophilic 2,4,5-trifluorophenyl pharmacophore. The...
8.
Pfefferkorn J, Lou J, Minich M, Filipski K, He M, Zhou R, et al.
Bioorg Med Chem Lett
. 2009 May;
19(12):3247-52.
PMID: 19435665
A promising area of novel anti-diabetic therapy involves identification of small molecule activators of the glucokinase enzyme to reduce blood glucose and normalize glucose stimulated insulin secretion. Herein, we report...
9.
Beebe D, Quinonez R, Shick E, Kim S, Kennedy D
Pediatr Dent
. 2009 Feb;
30(6):469-74.
PMID: 19186771
Purpose: The purpose of this study was to describe the failure rates of maxillary expansion appliances (MEAs) and assess risk variables associated with failures and treatment time. Methods: Retrospective chart...
10.
Mylari B, Armento S, Beebe D, Conn E, Coutcher J, Dina M, et al.
J Med Chem
. 2005 Sep;
48(20):6326-39.
PMID: 16190759
Discovery of a highly selective, potent, and safe non-carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the excess glucose flux through the polyol pathway that prevails...